Literature DB >> 9226143

Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

W B Brouwer1, M A Koopmanschap, F F Rutten.   

Abstract

This paper comments on the recently published guidelines of the Washington Panel on incorporation of indirect non-medical costs, or productivity costs, in economic evaluations of health care. Traditionally the human capital or more recently the friction cost method is used to measure these costs. The Panel, however, recommends incorporating productivity costs as health effects in the denominator of the C/E ratio. This paper argues that incorporation of productivity costs in cost-effectiveness analysis expressed as health effects is not correct. Only direct health related effects on quality of life that cannot be meaningfully monetarized should be considered as health effects. Furthermore, measuring productivity costs in terms of quality of life may lead to misrepresentation of these costs from a societal viewpoint. This misrepresentation occurs because of the existence of social security systems and private insurance compensating for income reductions from disease. Furthermore, the patient's viewpoint is useful for quality of life measurement, but not for measuring productivity costs from a societal perspective. Finally, alternative recommendations are formulated for incorporating societal productivity costs in economic evaluations of health care.

Entities:  

Mesh:

Year:  1997        PMID: 9226143     DOI: 10.1002/(sici)1099-1050(199705)6:3<253::aid-hec266>3.0.co;2-6

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  39 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  How to calculate indirect costs in economic evaluations.

Authors:  W B Brouwer; M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

3.  Does the EQ-5D reflect lost earnings?

Authors:  Carl Tilling; Marieke Krol; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

Review 4.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

5.  Validation of the work and health interview.

Authors:  Walter F Stewart; Judith A Ricci; Carol Leotta; Elsbeth Chee
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Productivity costs in health-state valuations : does explicit instruction matter?

Authors:  Marieke Krol; Werner Brouwer; Pedram Sendi
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.